Results 21 to 30 of about 1,551 (70)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview

Revista Brasileira de Hematologia e Hemoterapia, 2015
Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative ...
Renata Mendes de Freitas, Carlos Magno da Costa Maranduba   +1 more
doaj   +1 more source

Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms

International Journal of Gerontology, 2013
In addition to the JAK2 V617F mutation, somatic mutation in DNMT3A has been described in BCL-ABL1-negative myeloproliferative neoplasms (MPNs).
Huan-Chau Lin, Shu-Ching Wang, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Nai-Wen Su, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Chien-Chung Chang, Yuchi Hwang, Ken-Hong Lim, Yuan-Yeh Kuo   +13 more
doaj   +1 more source

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera

Journal of Hematology & Oncology, 2017
Background The driver mutations JAK2V617F, MPLW515L/K and CALR influence disease phenotype of myeloproliferative neoplasms (MPNs) and might sustain a condition of chronic inflammation.
Federico Lussana, Alessandra Carobbio, Silvia Salmoiraghi, Paola Guglielmelli, Alessandro Maria Vannucchi, Barbara Bottazzi, Roberto Leone, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi   +9 more
doaj   +1 more source

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Blood Cancer Journal, 2023
Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi   +14 more
doaj   +1 more source

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

Haematologica, 2010
Background Aberrant activation of tyrosine kinases, caused by either mutation or gene fusion, is of major importance for the development of many hematologic malignancies, particularly myeloproliferative neoplasms.
Thomas Ernst, Andrew Chase, Katerina Zoi, Katherine Waghorn, Claire Hidalgo-Curtis, Joannah Score, Amy Jones, Francis Grand, Andreas Reiter, Andreas Hochhaus, Nicholas C.P. Cross   +10 more
doaj   +1 more source

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Modernising diagnosis and treatment of Chronic Myeloid Leukaemia for improved patient outcomes in a resource-limited setting: Experiences from Ghana’s premier teaching hospital

Journal of Interventional Epidemiology and Public Health
Introduction: Until 2013, diagnosis of Chronic Myeloid Leukaemia (CML) at Korle-Bu Teaching Hospital (KBTH) in Ghana was based on white blood cell morphology ascertained from peripheral blood and bone marrow aspirate.
Amma Anima Benneh-Akwasi Kuma, Michael Mauro   +1 more
doaj   +1 more source

C019 | INIBITION OF PI3KΔ BY ROGINOLISIB (IOA-244) AS A POTENTIAL THERAPEUTIC STRATEGY FOR MYELOFIBROSIS

Haematologica
Due to its clonal stem cell origins and the resulting dysregulation of the JAK/STAT pathway, myelofibrosis (MF) treatment has undergone a paradigm shift with the development of JAK-inhibitors.
M. Balliu, G. Di Conza, M. Lahn, P. Guglielmelli, A.M. Vannucchi   +4 more
doaj  

P211 | NEUTROPHIL-TO-LYMPHOCYTES RATIOS CAN PREDICT OUTCOMES AND TREATMENT RESPONSE IN MYELOFIBROSIS PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

Haematologica
Background: Myelofibrosis (MF) is the most symptomatic form of MPN and carries the worst outcome. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and systemic inflammation response index
G. Capecchi, V. Boldrini, G. Coltro, G. G. Loscocco, L. Fagiolo, G. Borgi, C. Matteoli, T. Barbui, A.M. Vannucchi, P. Guglielmelli   +9 more
doaj